Chinese Journal of Integrative Medicine

, Volume 10, Issue 4, pp 289–295 | Cite as

Effect of Danshao Huaxian capsule on the expression of collagen I, III, and caspase-3 in hepatic fibrosis rats

  • Geng Xiao-xia
  • Yang Qin
  • Xie Ru-jia
  • Luo Xin-hua
  • Li Cheng-xiu
  • Cheng Ming-liang
Experimental Work and Research


Objective: To study the effect of Danshao Huaxian capsule (DSHX), a traditional Chinese medical prescription, on the expression of collagen (Col) I, III and cysteinyl aspartate specific proteases-3 (caspase-3) in CCl4-induced hepatic fibrosis in rats. And also it is to explore the mechanism of DSHX in anti-fibrosis.Methods: Eighty male Wistar rats were randomly divided into the normal control group (A), the model group (B), the un-treated model group (C), the low-dose-DSHX treated group (D) and the high-dose-DSHX treated group (E). Except those in Group A, all the other rats were made into hepatic fibrotic models by comprehensive processes including subcutaneous injecting of CCl4, and feeding them with alcoholic high-fat and low-protein diet for 8 weeks. Then the two DSHX-treated groups were treated respectively with low dose (0.5 g/kg) and high dose (1.0 g/kg) DSHX capsule by gastrogavage everyday for 8 weeks. At the end of the experiment, the liver index, levels of hyaluronic acid (HA) and alanine aminotransferase (ALT) in serum, degree of hepatic fibrosis, and urinary excretion of hydroxyproline (Hyp) were measured, and the expression of Col I, Col III and caspase-3 in liver tissues were detected respectively by immunohistochemistric technique.Results: Compared with those in Group B and C, the two DSHX treated groups showed that the liver index, levels of serum HA and ALT and severity of hepatic fibrosis were all significantly lower, the urinary excretion of Hyp was significantly higher; the Col I and Col-III expression was lower (Col I: 1.23±1.14, 1.07 ±0.96 vs 4.18±2.26, 3.22±1.44,P<0.01;Col III: 1.31±0.69, 1.09±0.58 vs 3.04±0.62, 2.23±0.58,P<0.05). At the same time, the expression of caspase-3 in Group E was fewer than Group B and C in hepatocytes (3.09±0.65 vs 9.60±2.32, 8.82±1.45,P<0.01), but it was extensively expressed in fibrous septal cells(4.52±0.87 vs 1.69±0. 23, 2. 98±0. 36,P<0.01).Conclusion: DSHX capsule shows certain therapeutic effect on hepatic fibrosis in rats, and the mechanism might be related with reducing Col I and Col III deposition, inhibiting hepatocyte apoptosis and promoting fibrous septal cells (mainly the activated hepatic stellate cells) apoptosis.

Key words

liver fibrosis collagen cysteinyl aspartate specific proteases-3 apoptosis traditional Chinese herbs 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weng HL, Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma 2 interferon on hepatic fibrosis. World J Gastroenterol 2001; 7: 42–48.PubMedGoogle Scholar
  2. 2.
    Li CX, Luo J, Li L, et al. The protective effects of Handan Ganle on CCl4-induced liver fibrosis in rats. Chin Public Health 1998; 14(9): 527–529.Google Scholar
  3. 3.
    Zhang HN, Li CX, Huang NH, et al. The preventive actions of traditional Chinese medicine Handan Ganle on immune liver fibrosis in rats. Guizhou Med J 2001; 25(5): 415–417.Google Scholar
  4. 4.
    Cheng ML, Ding YS, Luo YF, et al. The clinical research of the therapeutic effects of Handan Bituo on chronic active hepatitis. Chin J Integr Tradit West Med 1996; 16(7): 431–432.Google Scholar
  5. 5.
    Cheng ML, Yang CQ. The basic study and clinical research on hepatic fibrosis. Los Angeles: First Jumbo Publishing Co, 2002: 29–30.Google Scholar
  6. 6.
    Bissell DM. Connective tissue metabolism and hepatic fibrosis: an overview. Semin Liver Dis 1990; 10(1): iiiiv.Google Scholar
  7. 7.
    Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. J Gastroenterol 1997; 113(5): 1609–1614.CrossRefGoogle Scholar
  8. 8.
    Zheng M, Cai WM, Weng HL, et al. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis. Chin J Infect Dis 2002; 20(4): 225–227.Google Scholar
  9. 9.
    Ding HB, Chen YP, Feng XR, et al. Correlation analysis between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B. Chin J Hepatol 2001; 9(2): 78–80.Google Scholar
  10. 10.
    Gao CF, Ye WM, Xu LL, et al. Application study of serum markers in the diagnosis of fibrotic liver disease. Chin J Lab Med 2001; 24(2): 91–93.Google Scholar
  11. 11.
    Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin Liver Dis 1990; 10(1): 1–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatol 1995; 21(6): 1725–1741.Google Scholar
  13. 13.
    Lu P, Luo HS, Yu BP. Hepatocellular apoptosis and its apoptosis-regulating gene in rat liver fibrosis model. World J Gastroenterol 2001; 9(2): 165–169.Google Scholar
  14. 14.
    Zhang HL, Wang WL, Hu LZ. Detection of the mutation of p53 and K-ras genes and their expression products. J Fourth Milit Med Univ 1999; 20(9): 769–771.Google Scholar
  15. 15.
    Nagata S. Apoptosis by death factor. Cell 1997; 88(3): 355–365.PubMedCrossRefGoogle Scholar
  16. 16.
    Schulz JB, Weller M, Moskowitz MA. Caspases as treatment targets in stroke and neurodegenerative diseases. Ann Neurol 1999; 45(4): 421–429.PubMedCrossRefGoogle Scholar
  17. 17.
    Wolf BB, Schuler M, Echeverri F, et al. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem 1999; 274 (43): 30651–30656.PubMedCrossRefGoogle Scholar
  18. 18.
    Pawlowski J, Kraft AS. Bax-induced apoptosis. Proc Natl Acad Sci USA 2000; 97(2): 529–531.PubMedCrossRefGoogle Scholar
  19. 19.
    Tao J, Cai WM, Lu LW, et al. Expression of Bcl-2 and Bax proteins in rat liver fibrosis model and the role of IFN-γ. Chin J Hepatol 2003; 11(11): 669–672.Google Scholar
  20. 20.
    Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48 (4): 548–557.PubMedCrossRefGoogle Scholar
  21. 21.
    Jiang CM, Liu C, Liu P. The developing researches of the HSC during liver fibrosis. Chin J Dig 2000; 20(4): 258–260.Google Scholar
  22. 22.
    Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998; 29(5): 836–847PubMedCrossRefGoogle Scholar
  23. 23.
    Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19(2): 129–140.PubMedGoogle Scholar
  24. 24.
    Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998; 74(870): 193–202.PubMedGoogle Scholar
  25. 25.
    Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J Gastroenterol 2000; 35(9): 665–672.PubMedCrossRefGoogle Scholar
  26. 26.
    Wu YY, Cheng ML, Lu T, et al. Effect of Handan Ganle on the proliferation of fat-storing cell of mouse liver. Guizhou Med J 2000; 24(1): 15–16.Google Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 2004

Authors and Affiliations

  • Geng Xiao-xia
    • 1
  • Yang Qin
    • 2
  • Xie Ru-jia
    • 2
  • Luo Xin-hua
    • 3
  • Li Cheng-xiu
    • 4
  • Cheng Ming-liang
    • 1
  1. 1.Department of Infectious DiseasesAffiliated Hospital of Guiyang Medical CollegeGuizhou
  2. 2.Department of PathophisiologyGuiyang Medical CollegeChina
  3. 3.Department of Infectious DiseasesPeople’s Hospital of Guizhou ProvinceChina
  4. 4.Department of PharmacologyGuiyang Medical CollegeChina

Personalised recommendations